In July 2026 an FDA advisory committee voted on whether seven peptides should be eligible for use by compounding pharmacies. The result was widely reported as the FDA approving peptides. It was not that.
What was decided
| Peptide | Outcome | Vote |
|---|---|---|
| BPC-157 | Recommended | 8–6, 1 abstention |
| KPV | Recommended | 8–6, 1 abstention |
| TB-500 | Recommended | 8–6, 1 abstention |
| MOTS-c | Recommended | 7–5, 2 abstentions |
| Semax | Recommended | Narrow margin |
| Epitalon (Epithalon) | Recommended | Narrow margin |
| Emideltide (DSIP) | Rejected | 7–6, 1 abstention |
Meeting held 23–24 July 2026.
Four things the vote did not do
- It did not approve anything. Compounding eligibility is not drug approval, and none of these compounds is an approved medicine.
- It is not binding. The committee advises; the FDA decides.
- It went against FDA’s own scientists, who recommended against all seven, finding the studies short, small and insufficient to establish safety or effectiveness.
- Nothing has changed yet. Adding a substance requires a proposed rule, a public comment period and a final rule.
How long this takes
There is no statutory deadline. One prior example ran from a proposed rule in December 2016 to a final rule in February 2019, more than two years.
Why the votes were close
The margins reflect a genuine split. Advocates point to accumulated laboratory and animal work and to clinician demand. The agency’s scientists point to the absence of the controlled human trials that normally establish whether something works and is safe. The committee itself had been reshaped to include physicians from wellness and longevity practices, several with financial ties to the peptide industry.
If you see a vendor citing this vote as FDA endorsement, that is a misreading worth noticing: it tells you something about how carefully the rest of their claims are made.